Using EUS to analyze circulating tumor DNA in gastrointestinal cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to utilize endoscopic ultrasound (EUS) to perform portal vein and hepatic vein aspiration in patients with gastrointestinal cancers. By analyzing the concentration of circulating tumor DNA (ctDNA) in these veins and peripheral blood, the researchers hope to understand the liver's first pass effect in these patients. The study will explore the potential of ctDNA as a biomarker for preoperative staging, restaging after neoadjuvant chemotherapy, and monitoring for cancer recurrence. This minimally invasive approach could enhance genomic diagnostics for GI cancers.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Age \>= 18 years old
2. Newly diagnosed stage II-IV distal gastric cancer, pancreatic cancer or colorectal cancer
3. Undergoing treatment with either:

   1. Surgery
   2. Neoadjuvant chemotherapy
   3. Neoadjuvant chemoirradiation
   4. Palliative chemotherapy/ immunotherapy

      Exclusion criteria:

   <!-- -->

   1. Synchronous cancer of other sites
   2. Cardia, high lesser curve tumors, oesophagogastric junction tumors
   3. Presence of bulky lymph nodes at lesser curve/ coeliac region precluding a clear EUS puncture site to portal vein and hepatic vein
   4. Patients with coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count \<50,000x103/uL
   5. Patients unwilling to undergo follow-up assessments
   6. Patients with liver cirrhosis, portal hypertension and/ or gastric varices
   7. Patient refusal to participate

      \-

Where it's running

• The Chinese University of Hong Kong
  Hong Kong, Hong Kong Recruiting

Study contacts

• Study coordinator: Shannon Chan, FRCSEd
• Email: shannonchan@surgery.cuhk.edu.hk
• Phone: 852-35052627

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Frailty before GI cancer surgery: does frailty predict post-op outcomes in older adults?

  This study tests whether frailty measured before surgery can predict complications and recovery in patients 60 and older undergoing elective gastrointestinal cancer surgery.

  Recruiting Van Training and Research Hospital · Van, Van · NCT07815392

• Biological Collection to Help Create Models for Digestive Cancers and IBD

  Researchers are gathering tissue and biological samples from patients with inflammatory bowel disease or digestive cancers to build personalized models and test new therapies.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07782203

• Blood extracellular vesicles to detect chemotherapy-related nerve damage.

  We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07558447

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• XH001 with neoantigen vaccine–primed tumor-specific T cells for advanced gastrointestinal cancer

  This trial tests whether combining XH001 injections with T cells activated by a tumor neoantigen vaccine is safe and can shrink tumors or extend life in adults with advanced gastrointestinal cancer.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing · NCT07329894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.